Share this

FDA, Food and Drug Administration; EMA, European Medicines Agency; CDC, Centers of Disease Control and Prevention; PFU, plaque-forming units; TCID50, 50%
tissue culture infectious dose.

References:

  1. Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of licensure of
    ProQuad. https://www.fda.gov/media/165978/download. Accessed July 2026.
  2. ProQuad Summary of Product Characteristics.
  3. ProQuad Prescribing Information.
  4. M-M-R II Summary of Product Characteristics.
  5. Combination Vaccines – Fewer Shots Same Protection | CDC. Cdc.gov. 2023. Available at
    :https://www.cdc.gov/vaccines/parents/why-vaccinate/combination-vaccines.htm html. last accessed July, 2026.
  6. Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with
    hepatitis A and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012; 31(8): e133–e140.
  7. Bernstein HH, Eves K, Campbell K, et al. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles,
    mumps, rubella, and varicella virus vaccine live). Pediatrics. 2007; 119(6): e1299–e1305.

AE-QDX-00012 | Exp: 25 July 2028